Skip to main content
PRE
NASDAQ Life Sciences

Prenetics Q3 Revenue $64.1M Beats Guidance; 2H Adjusted EBITDA Loss Widened to $30-35M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$17.83
Mkt Cap
$276.593M
52W Low
$11.365
52W High
$27.24
52W Position info
57% above low
Off High info
35% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

PRE sits 57% above its 52-week low of $11.365.

Summary

Prenetics beat Q3 revenue guidance with $64.1 million, up about 228% year over year, but widened its second-half Adjusted EBITDA loss outlook to $30-35 million from $8-12 million as it pours more into customer acquisition. Cash still grew to $111.5 million, helped by $31.6 million of net fundings from the General Catalyst facility.


Key Events · Earnings and Guidance · PRE

  • Q3 Revenue Beats Guidance at $64.1M

    Total revenue of $64.1 million rose about 228% year over year and came in above the $63-64 million guided range; IM8 contributed $62.9 million, above its $61.5-62.5 million range.

  • 2H Adjusted EBITDA Loss Widened to $30-35M

    Guidance moved from the $8-12 million loss expected in August to $30-35 million, a deliberate increase in customer acquisition spend; at the midpoint that is about 23% of second-half revenue versus about 30% in the first half.

  • General Catalyst Facility Drew $31.6M Net

    First quarter of the $1 billion facility: $39.2 million received less $7.6 million remitted, leaving $34.7 million of borrowings on the balance sheet and positive $4.1 million Adjusted Free Cash Flow against $27.5 million of operating cash use.

  • CAC Fell to $285 on Record Spend

    Customer Acquisition Cost declined for a second straight quarter, to about $285 from $301, while acquisition marketing reached a record $39.3 million and new customers hit 137,892.


Analysis · PRE · Life Sciences

Revenue is running far ahead of plan — $64.1 million in Q3, up roughly 228% year over year and above the top of the $63-64 million range — but management deliberately doubled down on customer acquisition and now expects a second-half Adjusted EBITDA loss of $30-35 million instead of the $8-12 million guided in August. That is the number that will move the stock: the loss is a choice, funded up to 70% by General Catalyst's $1 billion facility, and the company says it will keep spending as long as cohort returns hold. The offsetting evidence is real — Customer Acquisition Cost fell to about $285 from $301 while spend hit a record $39.3 million, and cash rose to $111.5 million even in a record-spend quarter. The $7.2 million net loss swing is non-cash: a fair-value mark on warrant liabilities that rises when the share price rises, not new dilution or a cash outflow.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRE was trading at $17.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.6M. The 52-week trading range was $11.37 to $27.24. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRE - Latest Insights

PRE
Nov 18, 2026, 8:05 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $17.83
Real-time Price: $17.83 info
Change: $0 (0%) info
Market Cap: $276.593M info
PRE
Nov 17, 2026, 10:35 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $16.09
Real-time Price: $17.83 info
Change: +$1.74 (+11%) info
Market Cap: $276.593M info
PRE
Nov 05, 2026, 8:53 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $17.83 info
Change: +$1.63 (+10%) info
Market Cap: $276.593M info
PRE
Nov 05, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $17.83 info
Change: +$1.63 (+10%) info
Market Cap: $276.593M info
PRE
Nov 02, 2026, 9:13 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.23
Real-time Price: $17.83 info
Change: -$0.400 (-2%) info
Market Cap: $276.593M info